A team of specialists from the University of Sydney has published findings from a large-scale analysis in the scientific journal Pain, which could reshape conventional views on the potential of melatonin. This dietary supplement, long used to regulate sleep and combat insomnia, has demonstrated a clear analgesic effect in patients suffering from various forms of chronic pain syndromes.
The researchers conducted a systematic review of 23 randomized clinical trials involving a total of 2,028 volunteers. The sample included individuals dealing with chronic lower back pain, osteoarthritis, fibromyalgia, as well as patients recovering from surgical procedures.
Data analysis indicates that melatonin intake typically reduced pain intensity by 9 to 10 points on a hundred-point scale. The authors note that this effect is comparable to that of nonsteroidal anti-inflammatory drugs or even opioid analgesics, which are standard treatment options.
At the same time, participants experienced improvements in sleep quality. For those with chronic pain, sleep disturbances are often a concurrent issue that exacerbates the condition. Melatonin addresses both problems simultaneously, though experts acknowledge that the current findings are still preliminary.
The authors of the study do not view melatonin as a full replacement for standard therapy prescribed by a doctor. However, after mandatory consultation with a healthcare provider, it could be used as a supplementary aid, particularly for patients dealing with both chronic pain and persistent insomnia. The experts emphasize that any adjustments to medication regimens should be discussed with medical professionals to avoid unforeseen risks.
About the Author
